Hypera - About the company
Hypera is a public company based in Brazil. It operates as a Manufacturer of prescription and over-the-counter pharmaceuticals. The company has 4455 active competitors, including 125 funded and 333 that have exited. Its top competitors include companies like Abbott, WuXi AppTec and Precision Medicine Group.
Company Details
Manufacturer of prescription and over-the-counter pharmaceuticals, including generic medications, dermocosmetics, and nutritional supplements. It operates across various segments of the pharmaceutical sector, offering a diversified portfolio of products. The company invests in innovation and sustainable growth to improve people's health and well-being. Its product lines cater to both individual consumers and institutional clients such as clinics and hospitals.
Key Metrics
Hypera's IPO details
Hypera got listed on Apr 18, 2008.
Click here to take a look at Hypera's IPO in detail
Sign up to download Hypera's company profile
Hypera's funding and investors
Hypera has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Hypera's Competitors and alternates
Top competitors of Hypera include Abbott, WuXi AppTec and Precision Medicine Group. Here is the list of Top 10 competitors of Hypera, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Abbott 1888, Libertyville (United States), Public | Developer of medical devices, generic pharmaceuticals, and nutrition products | - | 76/100 | |
2nd | WuXi AppTec 2000, Shanghai (China), Public | Provider of CRO and CDMO services | $40M | 75/100 | |
3rd | Precision Medicine Group 2012, Bethesda (United States), Late Stage | Provider of clinical research, development, and commercialization services for life sciences | $532M | 72/100 | |
4th | ANI Pharmaceuticals 1996, Baudette (United States), Public | Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets | - | 64/100 | |
5th | Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | - | 63/100 | ||
6th | Neolife 1958, Fremont (United States), Unfunded | Provider of whole food nutritional supplements | - | - | 62/100 |
7th | Zuellig Pharma 1992, Singapore (Singapore), Funding Raised | Provider of clinical research, quality management, logistics, and clinical trial supply services | - | 61/100 | |
8th | Eurofins Scientific 1987, Luxembourg (Luxembourg), Public | Provider of laboratory testing services and CRO contract research services | - | 61/100 | |
9th | CDMO focused on manufacturing of plant based pharma, nutraceuticals, cosmetics, and other products | - | 60/100 | ||
10th | Herbalife 1980, Los Angeles (United States), Public | Manufacturer of nutritional supplement products for multiple therapeutic conditions | - | 60/100 | |
76th | Manufacturer of prescription and over-the-counter pharmaceuticals | - | - | 44/100 |
Looking for more details on Hypera's competitors? Click here to see the top ones
Hypera's Investments and acquisitions
Hypera has made no investments or acquisitions yet.
Reports related to Hypera
Here is the latest report on Hypera's sector:
News related to Hypera
Media has covered Hypera for a total of 8 events in the last 1 year, 2 of them have been about company updates and 1 about people movement.
•
Full Transcript: Hypera Q2 2026 Earnings Call - HYPERA SA S/ADR by Hypera SA (OTC:HYPMY)Benzinga•Sep 21, 2026•Hypera
•
Hypera Pharma posts R$490.2 million net profit in Q2, up 15% year-on-yearGrupoglobo•Aug 07, 2026•Hypera
•
Hypera: Financial impact of ending 6x1 schedule not expected to be significantGrupoglobo•Apr 29, 2026•Hypera
•
•
Hypera Announces Capital Increase of Up to R$ 1.5 Billion; Votorantim Will Lead the ContributionInvestNews•Feb 04, 2026•Hypera, Votorantim
•
•
Hypera creates control block and locks the door (for now) for new EMS acquisition investmentsNeofeed•Jul 08, 2025•Hypera
•
•
Votorantim Cimentos reports 2024 results, with a net profit decrease of 59%Grupoglobo•Mar 19, 2025•Votorantim Cimentos, Hypera
•
Hypera Pharma’s R$530 Million Debentures OfferingGlobal Legal Chronicle•Feb 14, 2025•LDR, Hypera, Banco do Brasil, Caixa and 2 others
Are you a Founder ?
FAQs about Hypera
Explore our recently published companies
- Baltas - Riga based, 2015 founded, Unfunded company
- CW Bearing - Hamburg based, 1996 founded, Unfunded company
- Jumbo Orient Contracting - China based, 1996 founded, Unfunded company
- NovoPSI - Russia based, Unfunded company
- Galaxy Technologies - Nagercoil based, Unfunded company
- AAFAQ AI - Unfunded company